On Jan 29, 2026, RMD reported earnings of 2.81 USD per share (EPS) for Q2 26, beating the estimate of 2.75 USD, resulting in a 2.15% surprise. Revenue reached 1.42 billion, compared to an expected 1.41 billion, with a 0.89% difference. The market reacted with a +0.27% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 17 analysts forecast an EPS of 2.80 USD, with revenue projected to reach 1.42 billion USD, implying an decrease of -0.36% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abbott Laboratories
Report Date
Jan 22, 2026 For Q4 25
Estimate
$1.51
Actual
$1.50
Surprise
-0.75%
Stryker Corporation
Report Date
Jan 29, 2026 For Q4 25
Estimate
$4.43
Actual
$4.47
Surprise
+0.69%
High Tide Inc. Common Shares
Report Date
Jan 29, 2026 For Q4 25
Estimate
$0.00
Actual
$0.01
Surprise
0.00%
FAQ
What were ResMed Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, ResMed Inc. reported EPS of $2.81, beating estimates by 2.15%, and revenue of $1.42B, 0.89% above expectations.
How did the market react to ResMed Inc.'s Q2 2026 earnings?
The stock price moved up 0.27%, changed from $257.61 before the earnings release to $258.31 the day after.
When is ResMed Inc. expected to report next?
The next earning report is scheduled for Apr 21, 2026.
What are the forecasts for ResMed Inc.'s next earnings report?
Based on 17
analysts, ResMed Inc. is expected to report EPS of $2.80 and revenue of $1.42B for Q3 2026.